555 related articles for article (PubMed ID: 27913065)
1. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M;
Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065
[TBL] [Abstract][Full Text] [Related]
2. Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG.
Löck S; Linge A; Lohaus F; Ebert N; Gudziol V; Nowak A; Tinhofer I; Kalinauskaite G; Guberina M; Stuschke M; Balermpas P; von der Grün J; Grosu AL; Debus J; Ganswindt U; Belka C; Peeken JC; Combs SE; De-Colle C; Zips D; Baretton GB; Krause M; Baumann M;
Radiother Oncol; 2022 Apr; 169():8-14. PubMed ID: 35182686
[TBL] [Abstract][Full Text] [Related]
3. HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Lohaus F; Linge A; Tinhofer I; Budach V; Gkika E; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Abdollahi A; Debus J; Bayer C; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; von Neubeck C; Baretton GB; Löck S; Thames HD; Krause M; Baumann M;
Radiother Oncol; 2014 Dec; 113(3):317-23. PubMed ID: 25480095
[TBL] [Abstract][Full Text] [Related]
4. Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(-) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG.
Linge A; Löck S; Gudziol V; Nowak A; Lohaus F; von Neubeck C; Jütz M; Abdollahi A; Debus J; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Avlar M; Grosu AL; Bayer C; Belka C; Pigorsch S; Combs SE; Welz S; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Baumann M; Krause M;
Clin Cancer Res; 2016 Jun; 22(11):2639-49. PubMed ID: 26755529
[TBL] [Abstract][Full Text] [Related]
5. Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy.
Linge A; Schmidt S; Lohaus F; Krenn C; Bandurska-Luque A; Platzek I; von Neubeck C; Appold S; Nowak A; Gudziol V; Buchholz F; Baretton GB; Baumann M; Löck S; Krause M
Clin Transl Radiat Oncol; 2019 May; 16():40-47. PubMed ID: 30993218
[TBL] [Abstract][Full Text] [Related]
6. Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy.
Linge A; Löck S; Krenn C; Appold S; Lohaus F; Nowak A; Gudziol V; Baretton GB; Buchholz F; Baumann M; Krause M
Clin Transl Radiat Oncol; 2016 Dec; 1():19-26. PubMed ID: 29657990
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy.
Patil S; Linge A; Grosser M; Lohaus F; Gudziol V; Kemper M; Nowak A; Haim D; Tinhofer I; Budach V; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Zips D; Baretton GB; Baumann M; Krause M; Löck S;
Radiother Oncol; 2022 Jun; 171():91-100. PubMed ID: 35429503
[TBL] [Abstract][Full Text] [Related]
8. Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC.
Linge A; Schötz U; Löck S; Lohaus F; von Neubeck C; Gudziol V; Nowak A; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Bunea H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Lauber K; Pigorsch S; Combs SE; Mönnich D; Zips D; Baretton GB; Buchholz F; Krause M; Belka C; Baumann M;
Radiother Oncol; 2018 Apr; 127(1):27-35. PubMed ID: 29295747
[TBL] [Abstract][Full Text] [Related]
9. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
10. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
11. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG).
Balermpas P; Rödel F; Rödel C; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Gkika E; Stuschke M; Avlar M; Grosu AL; Abdollahi A; Debus J; Bayer C; Stangl S; Belka C; Pigorsch S; Multhoff G; Combs SE; Mönnich D; Zips D; Fokas E
Int J Cancer; 2016 Jan; 138(1):171-81. PubMed ID: 26178914
[TBL] [Abstract][Full Text] [Related]
12. Tumor volume and cancer stem cell expression as prognostic markers for high-dose loco-regional failure in head and neck squamous cell carcinoma - A DAHANCA 19 study.
Kristensen MH; Sørensen MK; Tramm T; Alsner J; Sørensen BS; Maare C; Johansen J; Primdahl H; Bratland Å; Kristensen CA; Andersen M; Lilja-Fischer JK; Holm AIS; Samsøe E; Hansen CR; Zukauskaite R; Overgaard J; Eriksen JG
Radiother Oncol; 2024 Apr; 193():110149. PubMed ID: 38341096
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
Ou D; Garberis I; Adam J; Blanchard P; Nguyen F; Levy A; Casiraghi O; Gorphe P; Breuskin I; Janot F; Temam S; Scoazec JY; Deutsch E; Tao Y
Radiother Oncol; 2018 Jan; 126(1):116-124. PubMed ID: 29079308
[TBL] [Abstract][Full Text] [Related]
14. Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy.
Tawk B; Wirkner U; Schwager C; Rein K; Zaoui K; Federspil PA; Adeberg S; Linge A; Ganswindt U; Hess J; Unger K; Tinhofer I; Budach V; Lohaus F; Krause M; Guberina M; Stuschke M; Balermpas P; Rödel C; Grosu AL; Schäfer H; Zips D; Combs SE; Pigorsch S; Zitzelsberger H; Baumeister P; Kirchner T; Bewerunge-Hudler M; Weichert W; Hess J; Herpel E; Belka C; Baumann M; Debus J; Abdollahi A;
Int J Cancer; 2022 Feb; 150(4):603-616. PubMed ID: 34648658
[TBL] [Abstract][Full Text] [Related]
15. Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy.
Patil S; Tawk B; Grosser M; Lohaus F; Gudziol V; Kemper M; Nowak A; Haim D; Tinhofer I; Budach V; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Zips D; Baretton GB; Baumann M; Krause M; Löck S; Linge A;
Radiother Oncol; 2022 Feb; 167():300-307. PubMed ID: 34999136
[TBL] [Abstract][Full Text] [Related]
16. Treatment outcomes in veterans with HPV-positive head and neck cancer.
Feinstein AJ; Shay SG; Chang E; Lewis MS; Wang MB
Am J Otolaryngol; 2017; 38(2):188-192. PubMed ID: 28342482
[TBL] [Abstract][Full Text] [Related]
17. Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.
Descamps G; Karaca Y; Lechien JR; Kindt N; Decaestecker C; Remmelink M; Larsimont D; Andry G; Hassid S; Rodriguez A; Khalife M; Journe F; Saussez S
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2185-96. PubMed ID: 27370781
[TBL] [Abstract][Full Text] [Related]
18. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cell phenotype relates to radio-chemotherapy outcome in locally advanced squamous cell head-neck cancer.
Koukourakis MI; Giatromanolaki A; Tsakmaki V; Danielidis V; Sivridis E
Br J Cancer; 2012 Feb; 106(5):846-53. PubMed ID: 22333601
[TBL] [Abstract][Full Text] [Related]
20. The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenografts.
Linge A; Patil S; Grosser M; Lohaus F; Gurtner K; Kemper M; Gudziol V; Haim D; Nowak A; Tinhofer I; Zips D; Guberina M; Stuschke M; Balermpas P; Rödel C; Schäfer H; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Boeke S; Gani C; Jöhrens K; Baretton GB; Löck S; Baumann M; Krause M;
Radiother Oncol; 2024 Feb; 191():110055. PubMed ID: 38109944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
